Sarepta Therapeutics (SRPT) Current Deferred Revenue (2010 - 2026)
Sarepta Therapeutics' (SRPT) quarterly Current Deferred Revenue came in at $116.0 million in Q1 2026, up 158.67% year-on-year from $44.9 million in Q1 2025, and down 73.83% quarter-over-quarter from $443.4 million in Q4 2025.
Sarepta Therapeutics (SRPT) Current Deferred Revenue (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $116.0 million for Q1 2026.
- On a quarterly basis, Current Deferred Revenue rose 158.67% year-over-year to $116.0 million in Q1 2026; TTM through Mar 2026 was $116.0 million, a 158.67% increase from a year earlier, with the FY2025 full-year figure at $443.4 million, up 240.4% from the prior year.
- Current Deferred Revenue slipped to $116.0 million in Q1 2026 per SRPT's latest filing, from $443.4 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $485.4 million in Q3 2025 and bottomed at $22.5 million in Q3 2023.
- The 5-year median for Current Deferred Revenue is $89.2 million (2022), against an average of $148.2 million.
- Across the five-year window, Current Deferred Revenue slumped 74.79% in 2023 and soared 464.6% in 2024, its largest moves.
- Year by year, Current Deferred Revenue stood at $89.2 million in 2022, then tumbled by 43.51% to $50.4 million in 2023, then soared by 158.36% to $130.3 million in 2024, then soared by 240.4% to $443.4 million in 2025, then plunged by 73.83% to $116.0 million in 2026.
- Per Business Quant, the three latest SRPT Current Deferred Revenue figures stand at $116.0 million (Q1 2026), $443.4 million (Q4 2025), and $485.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Sarepta Therapeutics | 1.66 Bn | 1.25 Bn | 622.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116.04 Mn |
| Dec 31, 2025 | 443.40 Mn |
| Sep 30, 2025 | 485.45 Mn |
| Jun 30, 2025 | 395.43 Mn |
| Mar 31, 2025 | 44.86 Mn |
| Dec 31, 2024 | 130.26 Mn |
| Sep 30, 2024 | 127.00 Mn |
| Jun 30, 2024 | 122.04 Mn |
| Mar 31, 2024 | 112.00 Mn |
| Dec 31, 2023 | 50.42 Mn |
| Sep 30, 2023 | 22.49 Mn |
| Jun 30, 2023 | 44.99 Mn |
| Mar 31, 2023 | 67.24 Mn |
| Dec 31, 2022 | 89.24 Mn |
| Sep 30, 2022 | 89.24 Mn |
| Jun 30, 2022 | 89.24 Mn |
| Mar 31, 2022 | 89.24 Mn |
| Dec 31, 2021 | 89.24 Mn |
| Sep 30, 2021 | 89.24 Mn |
| Jun 30, 2021 | 89.24 Mn |